Martin G Schultz1, Dean S Picone1, Sonja B Nikolic1, Andrew D Williams2, James E Sharman3. 1. Menzies Institute for Medical Research, University of Tasmania, Australia. 2. School of Health Sciences, University of Tasmania, Australia. 3. Menzies Institute for Medical Research, University of Tasmania, Australia. Electronic address: James.Sharman@utas.edu.au.
Abstract
OBJECTIVES: Exaggerated exercise blood pressure (EEBP) recorded during exercise testing at moderate-intensity is independently associated with cardiovascular mortality. It is hypothesized that EEBP may be indicative of underlying hypertension unnoticed by standard clinic (resting) BP measures (thus explaining increased mortality risk), but this has never been confirmed by association with hypertension defined using ambulatory BP monitoring, which was the aim of this study. DESIGN: Cross-sectional study. METHODS: 100 consecutive patients free from coronary artery disease (aged 56±9 years, 72% male) underwent clinically indicated exercise stress testing. Exercise BP was recorded at each stage of the Bruce protocol. Presence of hypertension was defined as 24-hour systolic BP ≥130mmHg or daytime systolic BP ≥135mmHg. RESULTS: Exercise systolic BP at stage 1 and 2 of the test was significantly associated with the presence of hypertension (P<0.05), with the strongest association observed between stage 1 exercise systolic BP and 24-h systolic BP >130mmHg (AUC=0.752, 95% CI's 0.649-0.846, P<0.001). 79% of participants achieving systolic BP ≥150mmHg at stage 1 of the test were classified as having hypertension, with systolic BP >150mmHg predicting hypertension independently of age, sex and in-clinic hypertension status (OR=4.83, 95% CI's 1.62-14.39, P=0.005). CONCLUSIONS: Irrespective of resting BP, systolic BP ≥150mmHg during early stages of the Bruce exercise stress test is associated with presence of hypertension. EEBP should be a warning signal to health/exercise professionals on the presence of hypertension and the need to provide follow up care to reduce cardiovascular risk. Copyright Â
OBJECTIVES: Exaggerated exercise blood pressure (EEBP) recorded during exercise testing at moderate-intensity is independently associated with cardiovascular mortality. It is hypothesized that EEBP may be indicative of underlying hypertension unnoticed by standard clinic (resting) BP measures (thus explaining increased mortality risk), but this has never been confirmed by association with hypertension defined using ambulatory BP monitoring, which was the aim of this study. DESIGN: Cross-sectional study. METHODS: 100 consecutive patients free from coronary artery disease (aged 56±9 years, 72% male) underwent clinically indicated exercise stress testing. Exercise BP was recorded at each stage of the Bruce protocol. Presence of hypertension was defined as 24-hour systolic BP ≥130mmHg or daytime systolic BP ≥135mmHg. RESULTS: Exercise systolic BP at stage 1 and 2 of the test was significantly associated with the presence of hypertension (P<0.05), with the strongest association observed between stage 1 exercise systolic BP and 24-h systolic BP >130mmHg (AUC=0.752, 95% CI's 0.649-0.846, P<0.001). 79% of participants achieving systolic BP ≥150mmHg at stage 1 of the test were classified as having hypertension, with systolic BP >150mmHg predicting hypertension independently of age, sex and in-clinic hypertension status (OR=4.83, 95% CI's 1.62-14.39, P=0.005). CONCLUSIONS: Irrespective of resting BP, systolic BP ≥150mmHg during early stages of the Bruce exercise stress test is associated with presence of hypertension. EEBP should be a warning signal to health/exercise professionals on the presence of hypertension and the need to provide follow up care to reduce cardiovascular risk. Copyright Â
Authors: William E Hughes; David P Treichler; Kenichi Ueda; Joshua M Bock; Darren P Casey Journal: Nutr Metab Cardiovasc Dis Date: 2021-12-08 Impact factor: 4.222
Authors: Ömer Faruk Baycan; Fatma Betül Çelik; Tolga Sinan Güvenç; Adem Atıcı; Yusuf Yılmaz; Oğuz Konal; Mehmet Ali Ağırbaşlı; Şeref Kul; Hakan Güllü; Mustafa Çalışkan Journal: Hypertens Res Date: 2022-08-19 Impact factor: 5.528
Authors: Eduardo C Costa; Rodrigo A V Browne; Marcyo Câmara; Geovani A D Macêdo; Bruno E B Lucena; Lauro C Vianna; Todd A Duhamel Journal: J Clin Hypertens (Greenwich) Date: 2022-05-18 Impact factor: 2.885
Authors: Linha Lina M Mohammed; Meera Dhavale; Mohamed K Abdelaal; A B M Nasibul Alam; Tatjana Blazin; Dhruvil Prajapati; Jihan A Mostafa Journal: Cureus Date: 2020-12-09
Authors: Myles N Moore; Dean S Picone; Michele L Callisaya; Velandai Srikanth; James E Sharman; Martin G Schultz Journal: J Clin Hypertens (Greenwich) Date: 2019-10-22 Impact factor: 3.738
Authors: Martin G Schultz; Chloe Park; Abigail Fraser; Laura D Howe; Siana Jones; Alicja Rapala; George Davey Smith; James E Sharman; Deborah A Lawlor; Nish Chaturvedi; John Deanfield; Alun D Hughes Journal: Int J Cardiol Date: 2018-10-19 Impact factor: 4.164
Authors: Martin G Schultz; Katharine D Currie; Kristofer Hedman; Rachel E Climie; Andrew Maiorana; Jeff S Coombes; James E Sharman Journal: Int J Environ Res Public Health Date: 2022-02-28 Impact factor: 3.390